Royalty Pharma plc Derivative Asset, Noncurrent
Royalty Pharma plc (RPRX) had Derivative Asset, Noncurrent of $2.88 million as of 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DerivativeAssetsNoncurrent · last filed 2021-05-11
- 2021-03-31: Derivative Asset, Noncurrent $2.88M.
- 2020-12-31: Derivative Asset, Noncurrent $5.44M.
- 2020-09-30: Derivative Asset, Noncurrent $7.63M.
- 2020-06-30: Derivative Asset, Noncurrent $14.72M.
| Period end | Derivative Asset, Noncurrent |
|---|---|
| 2021-03-31 | $2.88M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $5.44M 10-Q · filed 2021-05-11 |
| 2020-09-30 | $7.63M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $14.72M 10-Q · filed 2020-08-12 |
| 2019-12-31 | $42.31M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |